Workflow
DILIsym
icon
Search documents
Simulations Plus Stock: Buying On Long-Term Silico Drug-Development (NASDAQ:SLP)
Seeking Alpha· 2025-12-03 02:41
Simulations Plus, Inc. ( SLP ) is a pure-play in silico platform for model-informed, non-animal drug development. The company combines software systems with services for clients. For example, they offer GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, and NAFLDsym, with services in QSP modeling, clinical pharmacology, training, and medical communications. That way, SLP'sMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Na ...
Simulations Plus: Buying On Long-Term Silico Drug-Development
Seeking Alpha· 2025-12-03 02:41
Company Overview - Simulations Plus, Inc. (SLP) operates as a pure-play in silico platform focused on model-informed, non-animal drug development [1] - The company integrates software systems with services tailored for clients, enhancing drug development processes [1] Product and Service Offerings - SLP provides a range of software products including GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, and NAFLDsym [1] - The company also offers services in quantitative systems pharmacology (QSP) modeling, clinical pharmacology, training, and medical communications [1]